Otto A Sanchez1, David R Jacobs, Hossein Bahrami, Carmen A Peralta, Lori B Daniels, João A Lima, Alan Maisel, Daniel A Duprez. 1. aSchool of Public Health, Division of Epidemiology & Community Health, University of Minnesota, Minneapolis, Minnesota bStanford University, Stanford cSchool of Medicine, University of California, San Francisco dDivision of Cardiology, University of California, San Diego, California eDivision of Cardiology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland fSchool of Medicine, University of California, San Diego, California gDivision of Cardiology, University of Minnesota, Minneapolis, Minnesota, USA.
Abstract
BACKGROUND: Longitudinal associations between the aminoterminal pro-B-type natriuretic peptide (NT-proBNP) and incident hypertension are lacking. METHODS: We tested associations between baseline NT-proBNP (bNT-proBNP) and change in NT-proBNP (ΔNT-proBNP) (visit 3 NT-proBNP - bNT-proBNP, 3.2 years apart) with incident hypertension (SBP ≥ 140 and/or DBP ≥90 mmHg or taking antihypertensive medications). Incident hypertension was evaluated in 5596 individuals in the Multi-Ethnic Study of Atherosclerosis without hypertension at baseline (53% women, age range 45-84 years without overt cardiovascular disease) and follow-up for 9.5 years and in a subgroup (1550) who had bNT-proBNP less than 100 pg/ml and no hypertension at visit 3. Incident hypertension was regressed (proportional hazards) on quintiles of bNT-proBNP (range) (reference <19.2, 19.3-40.8, 40.9-70.9, 71-135.2, and >135.5) and also on ΔNT-proBNP categories (reference <-10, -10 to 10, >10 to 50, and >50 pg/ml). Hazard ratios were adjusted for age, race, sex, education, diabetes, obesity, left ventricle mass/height, SBP and DBP, interleukin-6, salt intake, estimated glomerular filtration rate, and exercise. RESULTS: Compared with the reference category, hazard ratios (95% confidence interval) for incident hypertension compared with the first quintile of bNT-proBNP were 1.47 (1.13-1.93), 1.57 (1.18-2.09), 1.52 (1.12-2.06), and 2.36 (1.62-3.41). Hazard ratios for incident hypertension by categories of ΔNT-proBNP from 3.2 to 9.5 years follow-up were 0.98 (0.62-1.56), 1.13 (0.72-1.79), and 1.82 (1.07-3.12). CONCLUSION: The development of hypertension tended to be preceded by elevated levels of bNT-proBNP or a substantial positive ΔNT-proBNP.
BACKGROUND: Longitudinal associations between the aminoterminal pro-B-type natriuretic peptide (NT-proBNP) and incident hypertension are lacking. METHODS: We tested associations between baseline NT-proBNP (bNT-proBNP) and change in NT-proBNP (ΔNT-proBNP) (visit 3 NT-proBNP - bNT-proBNP, 3.2 years apart) with incident hypertension (SBP ≥ 140 and/or DBP ≥90 mmHg or taking antihypertensive medications). Incident hypertension was evaluated in 5596 individuals in the Multi-Ethnic Study of Atherosclerosis without hypertension at baseline (53% women, age range 45-84 years without overt cardiovascular disease) and follow-up for 9.5 years and in a subgroup (1550) who had bNT-proBNP less than 100 pg/ml and no hypertension at visit 3. Incident hypertension was regressed (proportional hazards) on quintiles of bNT-proBNP (range) (reference <19.2, 19.3-40.8, 40.9-70.9, 71-135.2, and >135.5) and also on ΔNT-proBNP categories (reference <-10, -10 to 10, >10 to 50, and >50 pg/ml). Hazard ratios were adjusted for age, race, sex, education, diabetes, obesity, left ventricle mass/height, SBP and DBP, interleukin-6, salt intake, estimated glomerular filtration rate, and exercise. RESULTS: Compared with the reference category, hazard ratios (95% confidence interval) for incident hypertension compared with the first quintile of bNT-proBNP were 1.47 (1.13-1.93), 1.57 (1.18-2.09), 1.52 (1.12-2.06), and 2.36 (1.62-3.41). Hazard ratios for incident hypertension by categories of ΔNT-proBNP from 3.2 to 9.5 years follow-up were 0.98 (0.62-1.56), 1.13 (0.72-1.79), and 1.82 (1.07-3.12). CONCLUSION: The development of hypertension tended to be preceded by elevated levels of bNT-proBNP or a substantial positive ΔNT-proBNP.
Authors: Carmen A Peralta; David R Jacobs; Ronit Katz; Joachim H Ix; Magdalena Madero; Daniel A Duprez; Mark J Sarnak; Michael H Criqui; Holly J Kramer; Walter Palmas; David Herrington; Michael G Shlipak Journal: Am J Kidney Dis Date: 2011-10-14 Impact factor: 8.860
Authors: Juliana Jensen; Li-Ping Ma; Michael L X Fu; David Svaninger; Per-Arne Lundberg; Ola Hammarsten Journal: Clin Res Cardiol Date: 2010-03-13 Impact factor: 5.460
Authors: N Tamura; Y Ogawa; H Chusho; K Nakamura; K Nakao; M Suda; M Kasahara; R Hashimoto; G Katsuura; M Mukoyama; H Itoh; Y Saito; I Tanaka; H Otani; M Katsuki Journal: Proc Natl Acad Sci U S A Date: 2000-04-11 Impact factor: 11.205
Authors: Michael H Freitag; Martin G Larson; Daniel Levy; Emelia J Benjamin; Thomas J Wang; Eric P Leip; Peter W F Wilson; Ramachandran S Vasan Journal: Hypertension Date: 2003-03-03 Impact factor: 10.190
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Christopher Newton-Cheh; Martin G Larson; Ramachandran S Vasan; Daniel Levy; Kenneth D Bloch; Aarti Surti; Candace Guiducci; Sekar Kathiresan; Emelia J Benjamin; Joachim Struck; Nils G Morgenthaler; Andreas Bergmann; Stefan Blankenberg; Frank Kee; Peter Nilsson; Xiaoyan Yin; Leena Peltonen; Erkki Vartiainen; Veikko Salomaa; Joel N Hirschhorn; Olle Melander; Thomas J Wang Journal: Nat Genet Date: 2009-02-15 Impact factor: 38.330
Authors: Nancy Swords Jenny; Elizabeth R Brown; Robert Detrano; Aaron R Folsom; Mohammed F Saad; Steven Shea; Moyses Szklo; David M Herrington; David R Jacobs Journal: Atherosclerosis Date: 2009-08-28 Impact factor: 5.162
Authors: O A Sanchez; D A Duprez; H Bahrami; C A Peralta; L B Daniels; J A Lima; A Maisel; A R Folsom; D R Jacobs Journal: Diabetes Metab Date: 2015-06-03 Impact factor: 6.041
Authors: Otto A Sanchez; Mariana Lazo-Elizondo; Irfan Zeb; Russell P Tracy; Ryan Bradley; Daniel A Duprez; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; David R Jacobs; Mathew J Budoff Journal: Metabolism Date: 2016-02-27 Impact factor: 8.694
Authors: Mohammad R Ostovaneh; Kasra Moazzami; Kihei Yoneyama; Bharath A Venkatesh; Susan R Heckbert; Colin O Wu; Steven Shea; Wendy S Post; Annette L Fitzpatrick; Gregory L Burke; Hossein Bahrami; Otto A Sanchez; Lori B Daniels; Erin D Michos; David A Bluemke; João A C Lima Journal: Hypertension Date: 2019-12-23 Impact factor: 10.190
Authors: Vinita Subramanya; Di Zhao; Pamela Ouyang; Wendy Ying; Dhananjay Vaidya; Chiadi E Ndumele; Joao A Lima; Eliseo Guallar; Ron C Hoogeveen; Sanjiv J Shah; Susan R Heckbert; David A Kass; Wendy S Post; Erin D Michos Journal: Biomarkers Date: 2021-03-09 Impact factor: 2.663
Authors: Yi-Ting Lin; Tove Fall; Ulf Hammar; Stefan Gustafsson; Erik Ingelsson; Johan Ärnlöv; Lars Lind; Gunnar Engström; Johan Sundström Journal: J Clin Med Date: 2019-10-02 Impact factor: 4.241
Authors: Julius Nikorowitsch; Francisco Ojeda; Karl J Lackner; Renate B Schnabel; Stefan Blankenberg; Tanja Zeller; Mahir Karakas Journal: Biomolecules Date: 2020-03-04